Skribe Medical Raises $1.65M in Pre-Seed Funding

Skribe Medical, a San Francisco, CA-based provider of wearable cardiac monitoring solutions for cancer care, has raised $1.65 million in a Pre-Seed funding round.

The round was led by SeaX Ventures, with participation from GoAhead Ventures and Marin Sonoma Impact Ventures.

The company will use the funding to support technology development and clinical research.

What is Skribe Medical?

Skribe Medical develops wearable technology to help monitor heart health in patients receiving cancer treatment.

Read More:Kindo Raises $30M to Expand Its Enterprise AI Platform

Its Aurora system combines a multi-sensor adhesive patch with AI-based analysis to estimate left ventricular ejection fraction (LVEF), a measure of how effectively the heart pumps blood.

Some cancer treatments can cause heart damage, a condition known as Cancer Therapy-Related Cardiac Dysfunction. Monitoring this risk often requires echocardiograms, which involve separate appointments and can delay treatment decisions.

Skribe aims to make cardiac assessments easier by allowing healthcare teams to check heart function during routine oncology visits. The company also plan's to support home based monitoring in the future.

How Much Funding Has Skribe Medical Raised?

Skribe Medical has raised $1.65 million in its pre-seed funding round. Details of previous funding rounds and its total funding to date were not provided.

Who Invested in Skribe Medical’s Pre-Seed Round?

The $1.65 million pre-seed round was led by SeaX Ventures.

Other participating investors included GoAhead Ventures and Marin Sonoma Impact Ventures. SeaX Ventures also helped arrange hospital collaborations in Southeast Asia and supported patient recruitment for the company's clinical study.

Why the Funding Matters

Heart related complications can affect patients receiving certain cancer therapies. Regular monitoring helps doctors identify potential problems but traditional echocardiograms require dedicated appointments and specialised equipment.

Skribe aims to make cardiac assessments more accessible through a wearable system that can be used during oncology visits. The new funding will support further technology development and clinical research to evaluate the system.

Its Aurora system was also selected for the US Food and Drug Administration's READI Home Innovation Challenge, which focuses on reducing hospital readmissions through home use devices. Participation provides an opportunity for early regulatory feedback but does not mean the product has received marketing authorisation.

Who founded Skribe Medical?

Skribe Medical was founded by Ryan Neely, Josh Kay and Andrew Bohannon. The company is headquartered in San Francisco, California.

Market and Business Growth

Skribe reports that more than 800 patients have enrolled in its NOECHO clinical study across 10 sites in the US and one site in Southeast Asia.

The study compares measurements from the Aurora system with echocardiography, which remains the established benchmark for assessing heart function.

The company is also developing a Resonant Body Power, and Communication platform designed to support battery free sensors.

What Happens Next?

Skribe plans to use the funding to advance its wearable technology, and continue clinical research.

A key priority is validating Aurora's measurements against echocardiography. The company aims to make cardiac monitoring available during oncology visits, with home based monitoring as a longer-term goal.

Read More:Araceli Biosciences Secures $4.5M in Funding